Schrödinger and TB Alliance announced a three-year research collaboration to speed the development of next-generation tuberculosis (TB) treatments by leveraging Schrödinger’s advanced computational platform for drug discovery. The joint team is focused on the discovery of efficacious inhibitors of PknB, which is essential for the growth of Mycobacterium tuberculosis (TB). Schrödinger’s computational platform has led the team to highly potent inhibitors with promising pharmacokinetic properties, after only a handful of design and optimization cycles. The next phase of the collaboration will involve in vivo efficacy studies and lead optimization to inform selection of a development candidate.